Lectures and seminars Hallmarks of cancer – reflections and conceptual evolution

Zoom details

join the meeting on this link:

https://ki-se.zoom.us/j/62353327154?pwd=a2dOSjBvMEhZUXV1U2grTUYvdEkyUT09

Meeting ID: 623 5332 7154

Passcode: 466048

Or dial +46 8 5050 0828 Sweden, +46 8 5050 0829 Sweden

Douglas Hanahan

Douglas Hanahan is a Distinguished Scholar at the Ludwig Institute for Cancer Research, Lausanne Branch and Professor of Molecular Oncology, and Former Director, Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne  (EPFL). He received a bachelor’s degree in Physics from MIT (1976), and a Ph.D. in Biophysics from Harvard (1983). He worked at Cold Spring Harbor Laboratory in New York (1978-88) initially as a graduate student and then as a group leader. From 1988-2010 he was on the faculty of the Department of Biochemistry & Biophysics at UCSF in San Francisco. He has been elected to the American Academy of Arts & Sciences (2007), the Institute of Medicine (USA) (2008), the US National Academy of Science (2009), and EMBO (2010). In 2011, Hanahan received an honorary degree from the University of Dundee (UK).In the 1980s, he developed one of the first transgenic mouse models of cancer. With Robert Weinberg, he wrote a seminal paper The Hallmarks of Cancer, published in January 2000, and which in March 2011 is the most often cited article from the peer reviewed journal Cell. In 2011, they published an updated review article entitled "Hallmarks of cancer: the next generation".In 2022, Douglas Hanahan published another updated review article entitled "Hallmarks of Cancer: New Dimensions" in Cancer Discovery.

The Hanahan group investigates tumor development and progression using genetically engineered mouse models of cancer that recapitulate important characteristics of human cancers, with strategic goals to elucidate pathogenic mechanisms underlying multi-step tumorigenesis and malignant progression, and to develop new therapeutic strategies based on knowledge of mechanism for translation to clinical trials aiming to improve the treatment of human cancers. Currently the lab focuses on melanoma, glioblastoma, pancreatic cancer, and squamous carcinomas elicited by human papillomaviruses.